Efficacy of First Line Dexamethasone, Rituximab and Cyclophosphamide (DRC) +/- Bortezomib for Patients With Waldenstrom's Macroglobulinemia

Trial Profile

Efficacy of First Line Dexamethasone, Rituximab and Cyclophosphamide (DRC) +/- Bortezomib for Patients With Waldenstrom's Macroglobulinemia

Recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Mar 2018

At a glance

  • Drugs Bortezomib (Primary) ; Cyclophosphamide; Dexamethasone; Rituximab
  • Indications Waldenstrom's macroglobulinaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Mar 2018 Planned End Date changed from 1 Dec 2022 to 1 Sep 2023.
    • 16 Mar 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Aug 2018.
    • 25 Oct 2016 This trial was suspended in Greece, according to European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top